Jasper Therapeutics, Inc.
JSPR
$0.73
$0.033.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.06% | -7.13% | -0.68% | 13.32% | 25.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.79% | -14.75% | 7.01% | 33.26% | 38.00% |
| Operating Income | 43.79% | 14.75% | -7.01% | -33.26% | -38.00% |
| Income Before Tax | 65.06% | 29.26% | -6.36% | -43.27% | -45.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.06% | 29.26% | -6.36% | -43.27% | -45.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.06% | 29.26% | -6.36% | -43.27% | -45.62% |
| EBIT | 43.79% | 14.75% | -7.01% | -33.26% | -38.00% |
| EBITDA | 43.60% | 14.30% | -7.56% | -34.55% | -38.39% |
| EPS Basic | 73.74% | 38.53% | 5.45% | -24.38% | -17.96% |
| Normalized Basic EPS | 75.83% | 40.92% | 8.03% | -22.02% | -17.21% |
| EPS Diluted | 73.74% | 38.53% | 5.45% | -24.38% | -17.96% |
| Normalized Diluted EPS | 75.83% | 40.92% | 8.03% | -22.02% | -17.21% |
| Average Basic Shares Outstanding | 70.08% | 48.80% | 29.70% | 14.04% | 19.92% |
| Average Diluted Shares Outstanding | 70.08% | 48.80% | 29.70% | 14.04% | 19.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |